Your browser is no longer supported. Please, upgrade your browser.
Settings
XBIO Xenetic Biosciences, Inc. daily Stock Chart
XBIO [NASD]
Xenetic Biosciences, Inc.
Index- P/E- EPS (ttm)-0.81 Insider Own58.20% Shs Outstand11.50M Perf Week-29.83%
Market Cap9.20M Forward P/E- EPS next Y- Insider Trans- Shs Float4.37M Perf Month-48.72%
Income-7.30M PEG- EPS next Q- Inst Own10.80% Short Float0.90% Perf Quarter-62.45%
Sales- P/S- EPS this Y-94.00% Inst Trans467.12% Short Ratio0.44 Perf Half Y-68.90%
Book/sh1.19 P/B0.67 EPS next Y- ROA- Target Price10.00 Perf Year-57.90%
Cash/sh0.17 P/C4.60 EPS next 5Y- ROE- 52W Range0.80 - 8.95 Perf YTD-51.23%
Dividend- P/FCF- EPS past 5Y19.40% ROI- 52W High-91.06% Beta2.24
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin- 52W Low-0.01% ATR0.13
Employees7 Current Ratio1.60 Sales Q/Q- Oper. Margin- RSI (14)20.79 Volatility9.89% 10.37%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.56 Prev Close0.80
ShortableYes LT Debt/Eq0.00 EarningsMay 29 BMO Payout- Avg Volume88.61K Price0.80
Recom1.00 SMA20-39.06% SMA50-51.46% SMA200-64.91% Volume49,499 Change-0.01%
May-14-19 07:42AM  The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings Benzinga
May-13-19 08:05AM  Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update ACCESSWIRE -5.00%
May-02-19 07:05AM  Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D. ACCESSWIRE -5.67%
Apr-01-19 07:30AM  Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update ACCESSWIRE
Mar-05-19 09:27AM  Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering ACCESSWIRE
Mar-04-19 08:00AM  Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform ACCESSWIRE -11.24%
Dec-04-18 02:57PM  What Investors Should Know About Xenetic Biosciences Incs (NASDAQ:XBIO) Financial Strength Simply Wall St.
Aug-14-18 11:37PM  Why Xenetic Biosciences Just Surged 28 Percent InvestorPlace -14.95%
08:05AM  Xenetic Biosciences Oncology Phase II Trial in Process, Pipeline Overview ACCESSWIRE
08:00AM  Todays Research Reports on Stocks to Watch: Xenetic Biosciences and Antares Pharma ACCESSWIRE
Jun-25-18 07:30AM  Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock ACCESSWIRE +103.90%
May-25-18 03:29PM  Interested In Xenetic Biosciences Inc (NASDAQ:XBIO)? Heres How It Performed Recently Simply Wall St. -13.71%
Feb-05-18 08:09PM  How Does Xenetic Biosciences Inc (NASDAQ:XBIO) Affect Your Portfolio Returns? Simply Wall St.
Jan-19-18 05:35PM  Xenetic Biosciences Inc (NASDAQ:XBIO): Is Now The Time To Bet On Healthcare? Simply Wall St.
Jan-02-18 04:29PM  Does Xenetic Biosciences Incs (NASDAQ:XBIO) CEO Pay Compared Well With Peers? Simply Wall St.
Dec-08-17 01:53PM  Who Really Owns Xenetic Biosciences Inc (XBIO)? Simply Wall St.
Nov-30-17 07:35PM  Does Xenetic Biosciences Incs (XBIO) 83.8% Earnings Growth Make It An Outperformer? Simply Wall St. -5.36%
Nov-15-17 07:05AM  Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update Business Wire
Nov-02-17 08:05AM  Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc Business Wire +26.70%
Oct-31-17 09:05AM  Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer Business Wire
Oct-04-17 01:16PM  How Should You Think About Xenetic Biosciences Incs (XBIO) Risks? Simply Wall St. -20.06%
Oct-02-17 10:45AM  Xenetic Biosciences Provides Update on Annual Meeting of Stockholders Business Wire -11.38%
Aug-23-17 08:05AM  Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders Business Wire
Aug-15-17 08:05AM  Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update Business Wire -9.57%
Aug-14-17 05:00PM  Xenetic Biosciences Announces Appointment of Three Directors to the Board Business Wire
Jul-18-17 04:05PM  Xenetic Biosciences Announces Adjournment of Annual Meeting of Stockholders until Wednesday, August 16, 2017 Business Wire
Jun-26-17 08:35AM  Xenetic Biosciences Commences Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction with Progestin Therapy for the Treatment of Endometrial Cancer Business Wire +9.88%
May-22-17 01:05PM  Shire and tiny Lexington biotech say hemophilia drug trial misses mark American City Business Journals
07:00AM  Xenetic Biosciences Receives Program Update from Partner Shires Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A Business Wire
May-16-17 07:00AM  Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update Business Wire -10.39%
May-09-17 08:35AM  Xenetic Biosciences to Host 2017 First Quarter Update Conference Call Business Wire
May-01-17 08:30AM  Xenetic Biosciences Presents Case Study of PolyXen Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston Business Wire
Apr-20-17 07:35AM  Xenetic Biosciences PolyXen Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston Business Wire
Apr-04-17 07:30PM  Edited Transcript of XBIO earnings conference call or presentation 4-Apr-17 12:30pm GMT Thomson Reuters StreetEvents
07:30PM  Edited Transcript of XBIO earnings conference call or presentation 4-Apr-17 12:30pm GMT
07:05AM  Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer Business Wire
07:05AM  Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer
Apr-03-17 07:35AM  Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update Business Wire
Mar-31-17 05:10PM  XENETIC BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
09:30AM  Prana Biotechnology and Xenetic Biosciences Expand Their Product Promotion Accesswire
Mar-29-17 10:56AM  Xenetic Biosciences, Inc. (Nasdaq: XBIO) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
07:35AM  Xenetic Biosciences to Ring Nasdaq Stock Market Opening Bell on March 30, 2017 Business Wire
Mar-27-17 08:05AM  Xenetic Biosciences Provides Update on Patent Portfolio Development Business Wire
Mar-09-17 08:00AM  Xenetic Biosciences to Present at the 29th Annual ROTH Conference Business Wire
Feb-27-17 03:49PM  XENETIC BIOSCIENCES, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
Jan-06-17 07:05AM  Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia Business Wire
Jan-04-17 05:27PM  XENETIC BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Ot
07:35AM  Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer Business Wire
Jan-03-17 07:35AM  Xenetic Biosciences to Present at Biotech Showcase 2017 Business Wire
Dec-20-16 07:16AM  Coverage initiated on Xenetic by Ladenburg Thalmann
Dec-15-16 11:48AM  Shire PLC (ADR) (SHPG) Looks To Xenetic Biosciences Inc (XBIO) To Cement Hemophilia Market Share at Insider Monkey
Dec-06-16 05:20PM  XENETIC BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Ot
Dec-05-16 07:05AM  Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer Business Wire
Dec-01-16 07:35AM  Xenetic Biosciences to Present at the LD Micro 2016 Annual Conference Business Wire
Nov-23-16 01:04PM  XENETIC BIOSCIENCES, INC. Financials
07:05AM  Xenetic Biosciences to Host Quarterly Update Conference Call and Webcast Business Wire
Nov-22-16 03:23PM  XENETIC BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Ot
Xenetic Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. Its proprietary drug development platform, PolyXen, enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company has a research, development, license, and supply agreements with Shire plc, Serum Institute of India, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Lexington, Massachusetts.